BIOMAT Database Logo BIOMAT Database Logo

The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. 1996

K de Vreese, and V Kofler-Mongold, and C Leutgeb, and V Weber, and K Vermeire, and S Schacht, and J Anné, and E de Clercq, and R Datema, and G Werner
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium.

Bicyclams are a novel class of antiviral compounds which act as potent and selective inhibitors of the replication of human immunodeficiency virus type 1 (HIV-1) and HIV-2. They block an early step in the viral life cycle following adsorption to the CD4 receptor and preceding reverse transcription. To identify the molecular target of these compounds, we genetically analyzed variants of the HIV-1 molecular clone NL4-3, which developed resistance against two structurally related bicyclams, JM2763 and the more potent SID791. The resistant strains were obtained after long-term passaging in MT-4 cells in the presence of progressively increasing compound concentrations. Recombinants between selected genes of the resistant strains and the parental NL4-3 provirus were generated by adapting the marker rescue technique to MT-4 cells. The bicyclam-resistant phenotype was rescued by transferring the envelope gp120 gene of bicyclam-resistant virus into the NL4-3 parental genetic background. In the gp120 genes of the resistant strains, we identified several mutations leading to amino acid substitutions in the V3 loop. Furthermore, two substitutions of highly conserved amino acids in close proximity to the disulfide bridges of the V3 and V4 loops were found in both SID791- and JM2763-resistant strains. Additional mutations in regions encoding V3, C4, V5, and C5 were present in SID791-resistant viruses. Recombination experiments with overlapping parts of the envelope gene indicated that most, if not all, of the mutations were necessary to develop the fully SID791 resistant phenotype. The mutations in the C-terminal part of gp120 downstream of the V3 loop sequence conferred partial resistance to JM2763 but did not significantly decrease susceptibility to SID791. The genetic data and the biological properties of the resistant viruses point to inhibition of entry and fusion as the mode of action of the HIV-inhibitory bicyclams. A possible mechanism of binding of bicyclams to gp120 leading to inhibition of unfolding of gp120 and its shedding from the gp41 fusion domain is discussed.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D006571 Heterocyclic Compounds Cyclic compounds that include atoms other than carbon in their ring structure. Heterocyclic Compound,Compound, Heterocyclic,Compounds, Heterocyclic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000080027 Cyclams Compounds made of fourteen-member tetraamine macrocycles which bind strongly to a wide range of metal ions. 1,4,8,11-Tetraazacyclotetradecane,Bicyclams,Cyclam Derivatives,Cyclens,Tetraazamacrocycles,Derivatives, Cyclam
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral

Related Publications

K de Vreese, and V Kofler-Mongold, and C Leutgeb, and V Weber, and K Vermeire, and S Schacht, and J Anné, and E de Clercq, and R Datema, and G Werner
The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding.
March 1996, Antiviral research,
K de Vreese, and V Kofler-Mongold, and C Leutgeb, and V Weber, and K Vermeire, and S Schacht, and J Anné, and E de Clercq, and R Datema, and G Werner
Bicyclams, selective antagonists of the human chemokine receptor CXCR4, potently inhibit feline immunodeficiency virus replication.
August 1999, Journal of virology,
K de Vreese, and V Kofler-Mongold, and C Leutgeb, and V Weber, and K Vermeire, and S Schacht, and J Anné, and E de Clercq, and R Datema, and G Werner
APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication.
December 2004, The Journal of biological chemistry,
K de Vreese, and V Kofler-Mongold, and C Leutgeb, and V Weber, and K Vermeire, and S Schacht, and J Anné, and E de Clercq, and R Datema, and G Werner
Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event.
June 1992, Proceedings of the National Academy of Sciences of the United States of America,
K de Vreese, and V Kofler-Mongold, and C Leutgeb, and V Weber, and K Vermeire, and S Schacht, and J Anné, and E de Clercq, and R Datema, and G Werner
Naturally occurring protease inhibitors potent against the human immunodeficiency virus.
October 1996, Biochemical and biophysical research communications,
K de Vreese, and V Kofler-Mongold, and C Leutgeb, and V Weber, and K Vermeire, and S Schacht, and J Anné, and E de Clercq, and R Datema, and G Werner
Sulfation of polysaccharides generates potent and selective inhibitors of human immunodeficiency virus infection and replication in vitro.
November 1987, Japanese journal of cancer research : Gann,
K de Vreese, and V Kofler-Mongold, and C Leutgeb, and V Weber, and K Vermeire, and S Schacht, and J Anné, and E de Clercq, and R Datema, and G Werner
U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication.
May 1993, Antimicrobial agents and chemotherapy,
K de Vreese, and V Kofler-Mongold, and C Leutgeb, and V Weber, and K Vermeire, and S Schacht, and J Anné, and E de Clercq, and R Datema, and G Werner
Griffithsin tandemers: flexible and potent lectin inhibitors of the human immunodeficiency virus.
January 2015, Retrovirology,
K de Vreese, and V Kofler-Mongold, and C Leutgeb, and V Weber, and K Vermeire, and S Schacht, and J Anné, and E de Clercq, and R Datema, and G Werner
Novel sulfated polymers as highly potent and selective inhibitors of human immunodeficiency virus replication and giant cell formation.
January 1990, Antimicrobial agents and chemotherapy,
K de Vreese, and V Kofler-Mongold, and C Leutgeb, and V Weber, and K Vermeire, and S Schacht, and J Anné, and E de Clercq, and R Datema, and G Werner
Clicking 3'-azidothymidine into novel potent inhibitors of human immunodeficiency virus.
November 2013, Journal of medicinal chemistry,
Copied contents to your clipboard!